08:01 AM EDT, 10/09/2024 (MT Newswires) -- Theratechnologies ( THTX ) on Wednesday announced three poster presentations at IDWeek 2024 taking place next week in Los Angeles.

One poster presents data linking excess visceral abdominal fat (EVAF) to increased cardiovascular risk in people with HIV, while a second poster documents how use of tesamorelin, a growth hormone-releasing factor analog, to reduce EVAF can lower cardiovascular disease risk in persons with HIV. The third poster reports on the study design and baseline characteristics of the PROMISE-US trial, an observational, real-world study of ibalizumab, a CD4-directed post-attachment inhibitor of HIV, in heavily treatment-experienced patients with multidrug resistance.

"The IDWeek poster presentations shed new light on important medical issues facing people with HIV," said Christian Marsolais, senior vice president and chief medical officer of Theratechnologies ( THTX ). "As people live longer with HIV and with greater exposure to anti-retroviral medicines, they may experience higher amounts of excess visceral abdominal fat and risk multidrug resistance. We look forward to sharing our findings with HIV clinicians and researchers at this premier meeting on infectious disease."

Theratechnologies ( THTX ) was last seen up US$0.06, to US$1.27 in U.S. premarket trade. It closed $0.07 lower at $1.63 on the Toronto Stock Exchange on Tuesday.